-
Posted by
Two Blokes Jul 23 -
Filed in
Stock
-
10 views
NanoViricides (NYSE-A:NNVC) said on Wednesday that its broad-spectrum antiviral candidate NV-387 has shown strong preclinical efficacy against multiple viruses, positioning it as a potential tool in global pandemic preparedness. The Connecticut-based biotech firm said its NV-387 compound has demonstrated effectiveness in animal studies against a wide range of viral threats, including MPox, Smallpox, Measles, Influenza, Coronaviruses, and other orthopoxviruses.
